Cellular/intramuscular myxoma and grade i myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 7, 2009, Pages 1291-1301

  Willems, Stefan M ^a   Mohseny, Alex B ^a   Balog, Crina ^a   Sewrajsing, Raj ^a   Briaire De Bruijn, Inge H ^a   Knijnenburg, Jeroen ^a   Cleton Jansen, Anne Marie ^a   Sciot, Raf ^b   Fletcher, Christopher D M ^c   Deelder, André M ^a   Szuhai, Karoly ^a   Hensbergen, Paul J ^a   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Extracellular matrix; GNAS; Intramuscular myxoma; Karyotype; LC MS; MLPA; Myxofibrosarcoma; Myxoid; Proteomics

Indexed keywords

GNAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN; SCLEROPROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ARTICLE; EXTRACELLULAR MATRIX; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MYXOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, LIQUID; DNA MUTATIONAL ANALYSIS; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYXOMA; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 68249127110     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00747.x     Document Type: Article

References (46)

1. Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM. Myxoid tumours of soft tissue. Histopathology. 1999 35 : 291 12.
2. Graadt van Roggen JF, McMenamin ME, Fletcher CDM. Cellular myxoma: a clinicopathologic study of 38 cases confirming indolent clinical behavior. Mod Pathol. 2001 39 : 287 97.
3. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996 20 : 391 05.
4. Meis-Kindblom JM, Sjogren H, Kindblom LG, et al. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch. 2001 439 : 141 51.
5. Willems SM, Debiec-Rychter M, Szuhai K, et al. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006 19 : 407 16.
6. Okamoto S, Hisaoka M, Ushijima M, et al. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch. 2000 437 : 133 37.
7. Candeliere GA, Glorieux FH, Prud'homme J, St.-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med. 1995 332 : 1546 51.
8. Kirsch DG, Dinulescu DM, Miller JB, et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007 13 : 992 97.
9. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 9 : 1941 56.
10. Oda Y, Takahira T, Kawaguchi K, et al. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol. 2003 34 : 1035 42.
11. Willems SM, Schrage YM, Baelde JJ, et al. Myxoid soft tissue tumours have a heterogeneous composition of their extra-cellular matrix. Histopathology. 2008 52 : 465 74.
12. Mentzel T, Van Den Berg E, Molenaar WM. Myxofibrosarcoma. World Health Organization classification of tumours: pathology and genetics. In : Fletcher CDM, Unni KK, and Mertens FL, editors. Tumours of soft tissue and bone. Lyon : IARC Press, 2004. pp. 102 03.
13. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984 33 : 37 42.
14. Szuhai K, Tanke H. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nat. Protoc. 2006 1 : 264 75.
15. De Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol. 2000 192 : 328 35.
16. Candeliere GA, Roughley PJ, Glorieux FH. Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone. 1997 21 : 201 06.
17. Bovée JVMG, Devilee P, Cornelisse CJ, et al. Identification of an EWS-pseudogene using translocation detection by RT-PCR in Ewing's sarcoma. Biochem Biophys Res Commun. 1995 213 : 1051 60.
18. Rozeman LB, Hameetman L, Cleton-Jansen AM, et al. Absence of IHH and retention of PTHrP signalling in enchon-dromas and central chondrosarcomas. J Pathol. 2005 205 : 476 82.
19. White SJ, Vink GR, Kriek M, et al. Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat. 2004 24 : 86 92.
20. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003 24 : 703 10.
21. Steen H, Pandey A, Andersen JS, Mann M. Analysis of tyrosine phosphorylation sites in signaling molecules by a phosphotyrosine-specific immonium ion scanning method. Sci STKE. 2002 2002 : L16.
22. Romeo S, Eyden B, Prins FA, et al. TGF-beta1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. J Pathol. 2006 208 : 26 34.
23. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002 3 : research0034.1-.11.
24. Rozeman LB, Hameetman L, van Wezel T, et al. cDNA expression profiling of central chondrosarcomas: Ollier disease resembles solitary tumors and alteration in genes coding for energy metabolism with increasing grade. J Pathol. 2005 207 : 61 71.
25. Koop K, Bakker RC, Eikmans M, et al. Differentiation between chronic rejection and chronic cyclosporine toxicity by analysis of renal cortical mRNA. Kidney Int. 2004 66 : 2038 46.
26. Bovée JVMG, Van Den Broek LJCM, et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest. 2000 80 : 1925 33.
27. Hoyland J, Sharpe PT. Upregulation of c-fos protooncogene expression in pagetic osteoclasts. J Bone Miner Res. 1994 9 : 1191 4.
28. Nielsen GP, O'Connell JX, Rosenberg AE. Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants. Am J Surg Pathol. 1998 22 : 1222 7.
29. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008 18 : 244 52.
30. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat. 1999 14 : 1 8.
31. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998 396 : 643 9.
32. Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome. Skeletal Radiol. 1999 28 : 522 6.
33. Weinstein LS, Liu J, Sakamoto A, et al. Minireview: GNAS: normal and abnormal functions. Endocrinology. 2004 145 : 5459 64.
34. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987 330 : 566 8.
35. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991 325 : 1688 95.
36. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004 23 : 2838 49.
37. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007 26 : 3279 90.
38. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005 1756 : 81 2.
39. Castagnola P, Giaretti W. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta. 2005 1756 : 115 25.
40. Ferdous Z, Wei VM, Iozzo R, et al. Decorin-transforming growth factor-interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem. 2007 282 : 35887 98.
41. Ruhland C, Schonherr E, Robenek H, et al. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillo-genesis. FEBS J. 2007 274 : 4246 55.
42. Canty EG, Kadler KE. Procollagen trafficking, processing and fibrillogenesis. J Cell Sci. 2005 118 : 1341 53.
43. Berrier AL, Yamada KM. Cell-matrix adhesion. J Cell Physiol. 2007 213 : 565 73.
44. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004 4 : 528 39.
45. Ehnis T, Dieterich W, Bauer M, et al. A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Exp Cell Res. 1996 229 : 388 97.
46. Romeo S, Debiec-Rychter M, Van Glabbecke M, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2009 15 : 4191 8.